

CureVac: Final Analysis of Pivotal Phase 2b/3 HERALD Study

July 1, 2021

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac Corporate Services GmbH (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and

collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Franz-Werner Haas

Introduction

Chief Executive Officer

Ulrike Gnad-Vogt

Final Analysis Data

Interim Chief Development Officer

Mariola Fotin-Mleczek

Q&A Availability

Chief Technology Officer


Pierre Kemula

Q&A Availability

Chief Financial Officer



The HERALD Study: Key Data from Final Analysis



15 COVID-19 STRAINS



48%

Efficacy of CVnCoV in the
prevention of COVID-19
cases of **any severity**

228

First episodes of
virologically-confirmed cases
of COVID-19 of **any severity**

PROTECTION IN AGE GROUP OF 18 TO 60

Hospitalization
and death

0 vs 6
(vaccine vs. placebo)


Moderate to
severe

77%


Any
severity

53%


The HERALD Study: Geographically Diverse and Multi-Variant




The HERALD Study: Sequencing Efforts Define Basis for Efficacy Calculation



COVID-19 Reality: Variants of Concern Spreading in Europe and Latin America




HERALD Study: Variant Diversity Defines Basis for Efficacy in Final Analysis



HERALD Study: Variant Diversity in Overall Study Reflect New COVID-19 Reality



- B.1 (wild type)
- B.1.1 (wild type)
- B.1.1.1 (wild type)
- B.1.1.7 (Alpha)
- B.1.351 (Beta)
- P.1 (Gamma)
- B.1.617.2 (Delta)
- B.1.429 (Epsilon)
- C.37 (Lambda)
- P.2 (Zeta)
- B.1.621 (Colombia)
- B.1.1.519 (Mexico)
- N.5
- P.1.2
- A.2.5
- B.1.111
- B.1.526
- B.1.623
- B.1.160
- B.1.177
- B.1.177.43
- B.1.1.348
- B.1.1.318
- B.1.177.73
- C.11
- C.36
- C.36.3
- B.1.177.53
- B.1.236



110

adjudicated +
non-adjudicated
cases


478


adjudicated +
non-adjudicated
cases

29 virus strains
overall

Efficacy Profile in Age Group 18 to 60 to Fight Pandemic and Variant Spread


IN THE AGE GROUP OF 18 TO 60






EFFICACY BY STRAIN AGAINST ANY SEVERITY (AGE GROUP OF 18 TO 60)

Variant	CVnCoV	Placebo	VE	LLCI	ULCI
B.1.621 (Colombia)	11	17	42	-25	73
Other	7	13	51	-24	80
Gamma (P.1)	9	26	67	30	85
Lambda (C.37)	13	26	53	8	76
Alpha (B.1.1.7)	20	42	55	24	74




Reactogenicity Data on First 2,000 Vaccinated Trial Participants

SYSTEMIC SYMPTOMS



LOCAL SYMPTOMS



1. Favorable CVnCoV **efficacy profile** established in predefined age group of **18 to 60**
2. In 18 to 60 age group, **77%** protection against **moderate/severe** disease and **full protection** against **hospitalization/death**
3. Efficacies calculated in view of the **combined** influence of **15 different variants**
4. In 18 to 60 age group, balanced and robust **efficacy trends per strain** shown in the range of **42%** (B.1.621) to **67%** (Gamma)
5. Favorable **safety profile** in line with other mRNA vaccines further confirms safe applicability of CVnCoV
6. Full commitment to **continue regulatory submission** pathway; ongoing dialogue with the EMA within the rolling submission review process





**Thank you for your
attention**

CureVac
www.curevac.com